References
(1) Jayson, G. C.; Kohn, E. C.; Kitchener, H. C.; Ledermann, J. A. Ovarian cancer. Lancet 2014 , 384 (9951), 1376-1388. DOI: 10.1016/S0140-6736(13)62146-7.
(2) Torre, L. A.; Trabert, B.; DeSantis, C. E.; Miller, K. D.; Samimi, G.; Runowicz, C. D.; Gaudet, M. M.; Jemal, A.; Siegel, R. L. Ovarian cancer statistics, 2018. CA Cancer J Clin 2018 ,68 (4), 284-296. DOI: 10.3322/caac.21456.
(3) Jelovac, D.; Armstrong, D. K. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011 ,61 (3), 183-203. DOI: 10.3322/caac.20113.
(4) Kuroki, L.; Guntupalli, S. R. Treatment of epithelial ovarian cancer. BMJ 2020 , 371 , m3773. DOI: 10.1136/bmj.m3773.
(5) Kalluri, R.; LeBleu, V. S. The biology. Science2020 , 367 (6478). DOI: 10.1126/science.aau6977.
(6) Cheng, L.; Hill, A. F. Therapeutically harnessing extracellular vesicles. Nat Rev Drug Discov 2022 . DOI: 10.1038/s41573-022-00410-w.
(7) Trams, E. G.; Lauter, C. J.; Salem, N.; Heine, U. Exfoliation of membrane ecto-enzymes in the form of micro-vesicles. Biochim Biophys Acta 1981 , 645 (1), 63-70. DOI: 10.1016/0005-2736(81)90512-5.
(8) Johnstone, R. M.; Adam, M.; Hammond, J. R.; Orr, L.; Turbide, C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem 1987 , 262 (19), 9412-9420.
(9) Pegtel, D. M.; Gould, S. J. Exosomes. Annu Rev Biochem2019 , 88 , 487-514. DOI: 10.1146/annurev-biochem-013118-111902.
(10) Mashouri, L.; Yousefi, H.; Aref, A. R.; Ahadi, A. M.; Molaei, F.; Alahari, S. K. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol Cancer 2019 ,18 (1), 75. DOI: 10.1186/s12943-019-0991-5.
(11) Nakamura, K.; Sawada, K.; Kobayashi, M.; Miyamoto, M.; Shimizu, A.; Yamamoto, M.; Kinose, Y.; Kimura, T. Role of the Exosome in Ovarian Cancer Progression and Its Potential as a Therapeutic Target.Cancers (Basel) 2019 , 11 (8). DOI: 10.3390/cancers11081147.
(12) Yu, W.; Hurley, J.; Roberts, D.; Chakrabortty, S. K.; Enderle, D.; Noerholm, M.; Breakefield, X. O.; Skog, J. K. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol2021 , 32 (4), 466-477. DOI: 10.1016/j.annonc.2021.01.074.
(13) Skotland, T.; Sandvig, K.; Llorente, A. Lipids in exosomes: Current knowledge and the way forward. Prog Lipid Res 2017 ,66 , 30-41. DOI: 10.1016/j.plipres.2017.03.001.
(14) Chen, H.; Wang, L.; Zeng, X.; Schwarz, H.; Nanda, H. S.; Peng, X.; Zhou, Y. Exosomes, a New Star for Targeted Delivery. Front Cell Dev Biol 2021 , 9 , 751079. DOI: 10.3389/fcell.2021.751079.
(15) Gurunathan, S.; Kang, M. H.; Jeyaraj, M.; Qasim, M.; Kim, J. H. Review of the Isolation, Characterization, Biological Function, and Multifarious Therapeutic Approaches of Exosomes. Cells2019 , 8 (4). DOI: 10.3390/cells8040307.
(16) Zhang, L.; Yu, D. Exosomes in cancer development, metastasis, and immunity. Biochim Biophys Acta Rev Cancer 2019 ,1871 (2), 455-468. DOI: 10.1016/j.bbcan.2019.04.004.
(17) Luo, Z.; Wang, Q.; Lau, W. B.; Lau, B.; Xu, L.; Zhao, L.; Yang, H.; Feng, M.; Xuan, Y.; Yang, Y.; et al. Tumor microenvironment: The culprit for ovarian cancer metastasis? Cancer Lett 2016 ,377 (2), 174-182. DOI: 10.1016/j.canlet.2016.04.038.
(18) Feng, W.; Dean, D. C.; Hornicek, F. J.; Shi, H.; Duan, Z. Exosomes promote pre-metastatic niche formation in ovarian cancer. Mol Cancer 2019 , 18 (1), 124. DOI: 10.1186/s12943-019-1049-4.
(19) Yang, Z.; Wang, W.; Zhao, L.; Wang, X.; Gimple, R. C.; Xu, L.; Wang, Y.; Rich, J. N.; Zhou, S. Plasma cells shape the mesenchymal identity of ovarian cancers through transfer of exosome-derived microRNAs. Sci Adv 2021 , 7 (9). DOI: 10.1126/sciadv.abb0737.
(20) Cai, J.; Gong, L.; Li, G.; Guo, J.; Yi, X.; Wang, Z. Exosomes in ovarian cancer ascites promote epithelial-mesenchymal transition of ovarian cancer cells by delivery of miR-6780b-5p. Cell Death Dis2021 , 12 (2), 210. DOI: 10.1038/s41419-021-03490-5.
(21) He, L.; Zhu, W.; Chen, Q.; Yuan, Y.; Wang, Y.; Wang, J.; Wu, X. Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis. Theranostics 2019 , 9 (26), 8206-8220. DOI: 10.7150/thno.37455.
(22) Sharma, S.; Alharbi, M.; Kobayashi, M.; Lai, A.; Guanzon, D.; Zuñiga, F.; Ormazabal, V.; Palma, C.; Scholz-Romero, K.; Rice, G. E.; et al. Proteomic analysis of exosomes reveals an association between cell invasiveness and exosomal bioactivity on endothelial and mesenchymal cell migration. Clin Sci (Lond) 2018 , 132 (18), 2029-2044. DOI: 10.1042/CS20180425.
(23) Alharbi, M.; Lai, A.; Guanzon, D.; Palma, C.; Zuñiga, F.; Perrin, L.; He, Y.; Hooper, J. D.; Salomon, C. Ovarian cancer-derived exosomes promote tumour metastasis. Clin Sci (Lond) 2019 , 133(13), 1401-1419. DOI: 10.1042/CS20190082.
(24) Pujade-Lauraine, E.; Banerjee, S.; Pignata, S. Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives. J Clin Oncol 2019 , 37 (27), 2437-2448. DOI: 10.1200/JCO.19.00194.
(25) Kanlikilicer, P.; Bayraktar, R.; Denizli, M.; Rashed, M. H.; Ivan, C.; Aslan, B.; Mitra, R.; Karagoz, K.; Bayraktar, E.; Zhang, X.; et al. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine 2018 ,38 , 100-112. DOI: 10.1016/j.ebiom.2018.11.004.
(26) Au Yeung, C. L.; Co, N. N.; Tsuruga, T.; Yeung, T. L.; Kwan, S. Y.; Leung, C. S.; Li, Y.; Lu, E. S.; Kwan, K.; Wong, K. K.; et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun2016 , 7 , 11150. DOI: 10.1038/ncomms11150.
(27) Zhu, X.; Shen, H.; Yin, X.; Yang, M.; Wei, H.; Chen, Q.; Feng, F.; Liu, Y.; Xu, W.; Li, Y. Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype.J Exp Clin Cancer Res 2019 , 38 (1), 81. DOI: 10.1186/s13046-019-1095-1.
(28) Alharbi, M.; Lai, A.; Sharma, S.; Kalita-de Croft, P.; Godbole, N.; Campos, A.; Guanzon, D.; Salas-Burgos, A.; Carrion, F.; Zuñiga, F. A.; et al. Extracellular Vesicle Transmission of Chemoresistance to Ovarian Cancer Cells Is Associated with Hypoxia-Induced Expression of Glycolytic Pathway Proteins, and Prediction of Epithelial Ovarian Cancer Disease Recurrence. Cancers (Basel) 2021 , 13 (14). DOI: 10.3390/cancers13143388.
(29) Dorayappan, K. D. P.; Wanner, R.; Wallbillich, J. J.; Saini, U.; Zingarelli, R.; Suarez, A. A.; Cohn, D. E.; Selvendiran, K. Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins. Oncogene 2018 , 37 (28), 3806-3821. DOI: 10.1038/s41388-018-0189-0.
(30) Asare-Werehene, M.; Nakka, K.; Reunov, A.; Chiu, C. T.; Lee, W. T.; Abedini, M. R.; Wang, P. W.; Shieh, D. B.; Dilworth, F. J.; Carmona, E.; et al. The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance. Oncogene2020 , 39 (7), 1600-1616. DOI: 10.1038/s41388-019-1087-9.
(31) Wang, J.; Yeung, B. Z.; Cui, M.; Peer, C. J.; Lu, Z.; Figg, W. D.; Guillaume Wientjes, M.; Woo, S.; Au, J. L. Exosome is a mechanism of intercellular drug transfer: Application of quantitative pharmacology.J Control Release 2017 , 268 , 147-158. DOI: 10.1016/j.jconrel.2017.10.020.
(32) Shenoy, G. N.; Loyall, J.; Maguire, O.; Iyer, V.; Kelleher, R. J.; Minderman, H.; Wallace, P. K.; Odunsi, K.; Balu-Iyer, S. V.; Bankert, R. B. Exosomes Associated with Human Ovarian Tumors Harbor a Reversible Checkpoint of T-cell Responses. Cancer Immunol Res 2018 ,6 (2), 236-247. DOI: 10.1158/2326-6066.CIR-17-0113.
(33) Zhou, J.; Li, X.; Wu, X.; Zhang, T.; Zhu, Q.; Wang, X.; Wang, H.; Wang, K.; Lin, Y. Exosomes Released from Tumor-Associated Macrophages Transfer miRNAs That Induce a Treg/Th17 Cell Imbalance in Epithelial Ovarian Cancer. Cancer Immunol Res 2018 , 6 (12), 1578-1592. DOI: 10.1158/2326-6066.CIR-17-0479.
(34) Chen, G.; Huang, A. C.; Zhang, W.; Zhang, G.; Wu, M.; Xu, W.; Yu, Z.; Yang, J.; Wang, B.; Sun, H.; et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.Nature 2018 , 560 (7718), 382-386. DOI: 10.1038/s41586-018-0392-8.
(35) Bhatta, M.; Shenoy, G. N.; Loyall, J. L.; Gray, B. D.; Bapardekar, M.; Conway, A.; Minderman, H.; Kelleher, R. J.; Carreno, B. M.; Linette, G.; et al. Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments. J Immunother Cancer 2021 , 9(10). DOI: 10.1136/jitc-2021-003148.
(36) Li, X.; Liu, Y.; Zheng, S.; Zhang, T.; Wu, J.; Sun, Y.; Zhang, J.; Liu, G. Role of exosomes in the immune microenvironment of ovarian cancer. Oncol Lett 2021 , 21 (5), 377. DOI: 10.3892/ol.2021.12638.
(37) Chen, Z.; Liang, Q.; Zeng, H.; Zhao, Q.; Guo, Z.; Zhong, R.; Xie, M.; Cai, X.; Su, J.; He, Z.; et al. Exosomal CA125 as A Promising Biomarker for Ovarian Cancer Diagnosis. J Cancer 2020 ,11 (21), 6445-6453. DOI: 10.7150/jca.48531.
(38) Felder, M.; Kapur, A.; Gonzalez-Bosquet, J.; Horibata, S.; Heintz, J.; Albrecht, R.; Fass, L.; Kaur, J.; Hu, K.; Shojaei, H.; et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.Mol Cancer 2014 , 13 , 129. DOI: 10.1186/1476-4598-13-129.
(39) Yang, C.; Kim, H. S.; Song, G.; Lim, W. The potential role of exosomes derived from ovarian cancer cells for diagnostic and therapeutic approaches. J Cell Physiol 2019 , 234(12), 21493-21503. DOI: 10.1002/jcp.28905.
(40) Lea, J.; Sharma, R.; Yang, F.; Zhu, H.; Ward, E. S.; Schroit, A. J. Detection of phosphatidylserine-positive exosomes as a diagnostic marker for ovarian malignancies: a proof of concept study. Oncotarget2017 , 8 (9), 14395-14407. DOI: 10.18632/oncotarget.14795.
(41) Soltész, B.; Lukács, J.; Szilágyi, E.; Márton, É.; Szilágyi Bónizs, M.; Penyige, A.; Póka, R.; Nagy, B. Expression of CD24 in plasma, exosome and ovarian tissue samples of serous ovarian cancer patients.J Biotechnol 2019 , 298 , 16-20. DOI: 10.1016/j.jbiotec.2019.03.018.
(42) Li, J.; Sherman-Baust, C. A.; Tsai-Turton, M.; Bristow, R. E.; Roden, R. B.; Morin, P. J. Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer2009 , 9 , 244. DOI: 10.1186/1471-2407-9-244.
(43) Wyciszkiewicz, A.; Kalinowska-Łyszczarz, A.; Nowakowski, B.; Kaźmierczak, K.; Osztynowicz, K.; Michalak, S. Expression of small heat shock proteins in exosomes from patients with gynecologic cancers.Sci Rep 2019 , 9 (1), 9817. DOI: 10.1038/s41598-019-46221-9.
(44) Shen, J.; Zhu, X.; Fei, J.; Shi, P.; Yu, S.; Zhou, J. Advances of exosome in the development of ovarian cancer and its diagnostic and therapeutic prospect. Onco Targets Ther 2018 , 11 , 2831-2841. DOI: 10.2147/OTT.S159829.
(45) Dorayappan, K. D. P.; Gardner, M. L.; Hisey, C. L.; Zingarelli, R. A.; Smith, B. Q.; Lightfoot, M. D. S.; Gogna, R.; Flannery, M. M.; Hays, J.; Hansford, D. J.; et al. A Microfluidic Chip Enables Isolation of Exosomes and Establishment of Their Protein Profiles and Associated Signaling Pathways in Ovarian Cancer. Cancer Res 2019 ,79 (13), 3503-3513. DOI: 10.1158/0008-5472.CAN-18-3538.
(46) Sun, Z.; Shi, K.; Yang, S.; Liu, J.; Zhou, Q.; Wang, G.; Song, J.; Li, Z.; Zhang, Z.; Yuan, W. Effect of exosomal miRNA on cancer biology and clinical applications. Mol Cancer 2018 , 17(1), 147. DOI: 10.1186/s12943-018-0897-7.
(47) Taylor, D. D.; Gercel-Taylor, C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer.Gynecol Oncol 2008 , 110 (1), 13-21. DOI: 10.1016/j.ygyno.2008.04.033.
(48) Kanlikilicer, P.; Rashed, M. H.; Bayraktar, R.; Mitra, R.; Ivan, C.; Aslan, B.; Zhang, X.; Filant, J.; Silva, A. M.; Rodriguez-Aguayo, C.; et al. Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells. Cancer Res 2016 , 76 (24), 7194-7207. DOI: 10.1158/0008-5472.CAN-16-0714.
(49) Pan, C.; Stevic, I.; Müller, V.; Ni, Q.; Oliveira-Ferrer, L.; Pantel, K.; Schwarzenbach, H. Exosomal microRNAs as tumor markers in epithelial ovarian cancer. Mol Oncol 2018 , 12(11), 1935-1948. DOI: 10.1002/1878-0261.12371.
(50) Meng, X.; Müller, V.; Milde-Langosch, K.; Trillsch, F.; Pantel, K.; Schwarzenbach, H. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget 2016 , 7(13), 16923-16935. DOI: 10.18632/oncotarget.7850.
(51) Lu, M.; Huang, Y. Bioinspired exosome-like therapeutics and delivery nanoplatforms. Biomaterials 2020 , 242 , 119925. DOI: 10.1016/j.biomaterials.2020.119925.
(52) Yang, B.; Chen, Y.; Shi, J. Exosome Biochemistry and Advanced Nanotechnology for Next-Generation Theranostic Platforms. Adv Mater 2019 , 31 (2), e1802896. DOI: 10.1002/adma.201802896.
(53) Barile, L.; Vassalli, G. Exosomes: Therapy delivery tools and biomarkers of diseases. Pharmacol Ther 2017 , 174 , 63-78. DOI: 10.1016/j.pharmthera.2017.02.020.
(54) Zhao, Z.; Shuang, T.; Gao, Y.; Lu, F.; Zhang, J.; He, W.; Qu, L.; Chen, B.; Hao, Q. Targeted delivery of exosomal miR-484 reprograms tumor vasculature for chemotherapy sensitization. Cancer Lett2022 , 530 , 45-58. DOI: 10.1016/j.canlet.2022.01.011.
(55) Li, L.; He, D.; Guo, Q.; Zhang, Z.; Ru, D.; Wang, L.; Gong, K.; Liu, F.; Duan, Y.; Li, H. Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer. J Nanobiotechnology 2022 , 20 (1), 50. DOI: 10.1186/s12951-022-01264-5.
(56) Pisano, S.; Pierini, I.; Gu, J.; Gazze, A.; Francis, L. W.; Gonzalez, D.; Conlan, R. S.; Corradetti, B. Immune (Cell) Derived Exosome Mimetics (IDEM) as a Treatment for Ovarian Cancer. Front Cell Dev Biol 2020 , 8 , 553576. DOI: 10.3389/fcell.2020.553576.
(57) Terlikowska, K. M.; Witkowska, A. M.; Zujko, M. E.; Dobrzycka, B.; Terlikowski, S. J. Potential application of curcumin and its analogues in the treatment strategy of patients with primary epithelial ovarian cancer. Int J Mol Sci 2014 , 15 (12), 21703-21722. DOI: 10.3390/ijms151221703.
(58) Patil, S.; Lis, L. G.; Schumacher, R. J.; Norris, B. J.; Morgan, M. L.; Cuellar, R. A.; Blazar, B. R.; Suryanarayanan, R.; Gurvich, V. J.; Georg, G. I. Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts. J Med Chem2015 , 58 (23), 9334-9344. DOI: 10.1021/acs.jmedchem.5b01329.
(59) Hu, Y.; Ran, M.; Wang, B.; Lin, Y.; Cheng, Y.; Zheng, S. Co-Delivery of Docetaxel and Curcumin via Nanomicelles for Enhancing Anti-Ovarian Cancer Treatment. Int J Nanomedicine 2020 ,15 , 9703-9715. DOI: 10.2147/IJN.S274083.
(60) He, D.; Xu, X.; Li, L.; Chen, C.; Gong, K.; Guo, Q.; Liu, F.; Wang, Y.; Duan, Y.; Li, H. Functional Exosome-Mediated Delivery of Triptolide Endowed with Targeting Properties as Chemotherapy Carriers for Ovarian Carcinoma. J Biomed Nanotechnol 2021 , 17 (3), 426-438. DOI: 10.1166/jbn.2021.3041.
(61) Kennedy, L. B.; Salama, A. K. S. A review of cancer immunotherapy toxicity. CA Cancer J Clin 2020 , 70 (2), 86-104. DOI: 10.3322/caac.21596.
(62) Xu, Z.; Zeng, S.; Gong, Z.; Yan, Y. Exosome-based immunotherapy: a promising approach for cancer treatment. Mol Cancer2020 , 19 (1), 160. DOI: 10.1186/s12943-020-01278-3.
(63) Li, Y.; Yang, Y.; Xiong, A.; Wu, X.; Xie, J.; Han, S.; Zhao, S. Comparative Gene Expression Analysis of Lymphocytes Treated with Exosomes Derived from Ovarian Cancer and Ovarian Cysts. Front Immunol 2017 , 8 , 607. DOI: 10.3389/fimmu.2017.00607.
(64) Peng, P.; Yan, Y.; Keng, S. Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-tumor immunity. Oncol Rep 2011 , 25 (3), 749-762. DOI: 10.3892/or.2010.1119.
(65) Andre, F.; Schartz, N. E.; Movassagh, M.; Flament, C.; Pautier, P.; Morice, P.; Pomel, C.; Lhomme, C.; Escudier, B.; Le Chevalier, T.; et al. Malignant effusions and immunogenic tumour-derived exosomes.Lancet 2002 , 360 (9329), 295-305. DOI: 10.1016/S0140-6736(02)09552-1.
(66) Yu, S.; Cao, H.; Shen, B.; Feng, J. Tumor-derived exosomes in cancer progression and treatment failure. Oncotarget2015 , 6 (35), 37151-37168. DOI: 10.18632/oncotarget.6022.
(67) Li, Q. L.; Bu, N.; Yu, Y. C.; Hua, W.; Xin, X. Y. Exvivo experiments of human ovarian cancer ascites-derived exosomes presented by dendritic cells derived from umbilical cord blood for immunotherapy treatment. Clin Med Oncol 2008 , 2 , 461-467. DOI: 10.4137/cmo.s776.
(68) Dorayappan, K. D. P.; Wallbillich, J. J.; Cohn, D. E.; Selvendiran, K. The biological significance and clinical applications of exosomes in ovarian cancer. Gynecol Oncol 2016 , 142 (1), 199-205. DOI: 10.1016/j.ygyno.2016.03.036.
(69) Marleau, A. M.; Chen, C. S.; Joyce, J. A.; Tullis, R. H. Exosome removal as a therapeutic adjuvant in cancer. J Transl Med2012 , 10 , 134. DOI: 10.1186/1479-5876-10-134.
(70) Colombo, M.; Raposo, G.; Théry, C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles.Annu Rev Cell Dev Biol 2014 , 30 , 255-289. DOI: 10.1146/annurev-cellbio-101512-122326.
(71) Ostrowski, M.; Carmo, N. B.; Krumeich, S.; Fanget, I.; Raposo, G.; Savina, A.; Moita, C. F.; Schauer, K.; Hume, A. N.; Freitas, R. P.; et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol 2010 , 12 (1), 19-30; sup pp 11-13. DOI: 10.1038/ncb2000.
(72) Trajkovic, K.; Hsu, C.; Chiantia, S.; Rajendran, L.; Wenzel, D.; Wieland, F.; Schwille, P.; Brügger, B.; Simons, M. Ceramide triggers budding of exosome vesicles into multivesicular endosomes.Science 2008 , 319 (5867), 1244-1247. DOI: 10.1126/science.1153124.
(73) Shimizu, A.; Sawada, K.; Kobayashi, M.; Yamamoto, M.; Yagi, T.; Kinose, Y.; Kodama, M.; Hashimoto, K.; Kimura, T. Exosomal CD47 Plays an Essential Role in Immune Evasion in Ovarian Cancer. Mol Cancer Res 2021 , 19 (9), 1583-1595. DOI: 10.1158/1541-7786.MCR-20-0956.